National Programme FOR TB Pharmaceutical Import Profile — Sri Lanka (DGFT 2022–2026)

Name: National Programme FOR TB Pharmaceutical Import Records from India — 3 Products, $450.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

National Programme FOR TB — Pharmaceutical Importer Profile (2026) | 3 Products, $450.0K Trade | TransData Nexus

Who Are the Verified Indian Suppliers to National Programme FOR TB?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Macleods Pharmaceuticals Limited	$250.0K	5	100.0%

National Programme FOR TB sources from 1 verified Indian supplier across 5 distinct formulations. The sourcing is highly concentrated — Macleods Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does National Programme FOR TB Import?

Formulation	Value	Ships
Rifampicin 150 MG / isoniazid 75 MG / ethambutol hydrochloride 275 MG tablets. (24x28's) (429 Pack)	$50.0K	1
Rifampicin capsules BP 150MG. (10x10's)(3887 Pack)	$50.0K	1
Ethambutol hydrochloride 100MG tablets.(10x10's) (1461 Pack)	$50.0K	1
Rifampicin 75MG / isoniazid 50MG / pyrazinamide 150MG disp tablets. (3x28's) (581 Pack)	$50.0K	1
Rifampicin 75MG /isoniazid 50MG dispersible tablets. (3x28's) (1371 Pack)	$50.0K	1

National Programme FOR TB imports 5 distinct pharmaceutical formulations. Showing top 5 by value. For full formulation-level data, contact TransData Nexus.

What Products Does National Programme FOR TB Import?

Top Products by Import Value

1Rifampicin$200.0K 2Isoniazid$150.0K 3Ethambutol$100.0K

National Programme FOR TB Therapeutic Categories — 2 Specializations

National Programme FOR TB imports across 2 therapeutic categories, with Tuberculosis Medications (55.6%), Advanced Antibiotics (44.4%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Tuberculosis Medications

2 products · 55.6% · $250.0K

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Rifampicin	Advanced Antibiotics	$200.0K	4	0.0%	6
2	Isoniazid	Tuberculosis Medications	$150.0K	3	0.0%	9

Key Metrics

Total Import Value$450.0K

Products3

Shipments9

Categories2

CountrySri Lanka

#1 Rankings0

Indian Suppliers1

Formulations5

Top Categories

Tuberculosis Medications55.6%

Advanced Antibiotics44.4%

Last updated: March 28, 2026

National Programme FOR TB — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

The National Programme for Tuberculosis Control and Chest Diseases (NPTCCD) is the central organization under Sri Lanka's Ministry of Health, dedicated to controlling and preventing tuberculosis (TB) and other respiratory diseases nationwide. Established in 2001, NPTCCD coordinates and monitors TB and chest disease control activities, aiming to create a TB-free Sri Lanka. (nptccd.health.gov.lk)

As a government entity, NPTCCD is not a pharmaceutical buyer or importer. Instead, it focuses on policy formulation, planning, coordination, and monitoring of TB and chest disease control activities across the country. The organization operates through district chest clinics covering all 26 districts, providing free diagnostic and treatment services to TB patients. (nptccd.health.gov.lk)

2Distribution Network

NPTCCD's distribution network comprises district chest clinics located throughout Sri Lanka, ensuring nationwide coverage for TB control and prevention. These clinics are strategically positioned to provide accessible diagnostic and treatment services to the population. The organization collaborates with various stakeholders, including the World Health Organization and the Global Fund, to strengthen its logistics capabilities and enhance service delivery. (nptccd.health.gov.lk)

Supplier Relationship Intelligence — National Programme FOR TB

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

NPTCCD's procurement strategy for TB medications involves sourcing from a limited number of suppliers to maintain consistency and quality. The organization has engaged with a single supplier, MACLEODS PHARMACEUTICALS LIMITED, for its TB medication needs. This single-source dependency may present risks related to supply chain disruptions or changes in supplier terms. However, the consistent sourcing from one supplier suggests a strategic choice to ensure uniformity in product quality and availability. The five shipments from MACLEODS PHARMACEUTICALS LIMITED indicate a stable and ongoing relationship, which is crucial for maintaining uninterrupted supply and quality control.

2Supply Chain Resilience

NPTCCD's supply chain resilience is closely tied to its relationship with MACLEODS PHARMACEUTICALS LIMITED. The organization's reliance on a single supplier for TB medications could pose challenges in the event of supply chain disruptions, such as production delays or logistical issues. Diversifying suppliers and formulations could enhance resilience by mitigating risks associated with single-source dependency. Additionally, ensuring that suppliers comply with international Good Manufacturing Practice (GMP) standards is essential for maintaining the quality and safety of TB medications.

3Strategic Implications

NPTCCD's sourcing pattern, characterized by a single-source dependency, has strategic implications for its competitive position in the pharmaceutical supply chain. While this approach ensures consistency in product quality, it also exposes the organization to potential risks associated with supply chain disruptions. For Indian exporters seeking to become alternative suppliers, understanding NPTCCD's procurement strategy is crucial. Offering competitive pricing, ensuring compliance with international quality standards, and demonstrating reliability in supply chain management could position new suppliers favorably in NPTCCD's procurement considerations.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Sri Lanka — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Sri Lanka

1Regulatory Authority & Framework

The National Medicines Regulatory Authority (NMRA) is the primary regulatory body overseeing pharmaceutical imports in Sri Lanka. Established in 2015, NMRA operates under the Ministry of Health and is responsible for ensuring the safety, efficacy, and quality of medicinal products, medical devices, and borderline products. The NMRA enforces regulations that govern the importation, registration, and distribution of pharmaceutical products, aiming to protect public health by maintaining stringent standards throughout the pharmaceutical supply chain.

Key legislation governing pharmaceutical imports includes the Medicines (Pricing Mechanism for Medicines) Regulations, which establish a standardized pricing formula for imported medicines. This formula considers the Cost, Insurance, and Freight (CIF) value, the Supply Chain Total Markup (SCTM), and applicable duties and taxes to determine the Maximum Retail Price (MRP) of medicines. The NMRA reviews and revises the MRP during new registration, re-registration, renewal, or when issuing a new import license, ensuring that prices remain competitive and sustainable.

2Import Licensing & GMP

Import licensing requirements in Sri Lanka mandate that all pharmaceutical products be registered with the NMRA before importation. Import license applications should be submitted at least twelve weeks in advance to avoid delays. As of February 2026, the NMRA has introduced new requirements for price submissions, particularly for import licenses that expire on or after 1st February 2026. Importers must provide price details through a specified format, along with evidence of importation during the past two years or proof of participation in tenders.

Good Manufacturing Practice (GMP) certification is essential for pharmaceutical imports. The NMRA recognizes GMP certificates from reputable authorities, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications to comply with NMRA standards. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within Sri Lanka.

3Quality & Labeling

Pharmaceutical products imported into Sri Lanka must undergo batch testing to verify their quality and safety. Stability requirements ensure that products maintain their efficacy and safety throughout their shelf life. Labeling must include information in writing, with unit-level traceability to enable granular tracking of products. As of December 2025, all imported finished pharmaceutical products must carry a price-marked label before being released to the local market. The label must clearly display the Maximum Retail Price (MRP) and the name and address of the local Marketing Authorization Holder (MAH) or importer. (softgroup.eu)

4Recent Regulatory Changes

Between 2024 and 2026, the NMRA has implemented several policy changes affecting pharmaceutical imports into Sri Lanka. Notably, in February 2026, the NMRA introduced new requirements for price submissions for import licenses expiring on or after 1st February 2026. Importers must now provide price details through a specified format, along with evidence of importation during the past two years or proof of participation in tenders. These changes aim to enhance transparency and control over pharmaceutical pricing in the country.

TransData Nexus Research · Sri Lanka regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: National Programme FOR TB identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as National Programme FOR TB's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 9 individual customs records matching National Programme FOR TB.
5.Supplier Verification: National Programme FOR TB sources from 1 verified Indian suppliers across 5 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

3 Products Tracked

2 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

National Programme FOR TB

National Programme FOR TB — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to National Programme FOR TB?

What Formulations Does National Programme FOR TB Import?

What Products Does National Programme FOR TB Import?

Top Products by Import Value

National Programme FOR TB Therapeutic Categories — 2 Specializations

Import Portfolio — Top 3 by Import Value

Key Metrics

Top Categories

National Programme FOR TB — Corporate Profile & Information

1Company Overview

2Distribution Network

Indian Suppliers

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — National Programme FOR TB

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Sri Lanka — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

National Programme FOR TB — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to National Programme FOR TB

1Opportunity Assessment

2Requirements & Qualifications

Frequently Asked Questions — National Programme FOR TB

What products does National Programme FOR TB import from India?

Who supplies pharmaceuticals to National Programme FOR TB from India?

What is National Programme FOR TB's total pharmaceutical import value?

What therapeutic categories does National Programme FOR TB focus on?

Get Full National Programme FOR TB Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology